You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Optimizing Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer

  • Authors: Maha Hussain, MD, FACP, FASCO; Emily Lemke, DNP; Fred Saad, MD, FRCS; Thomas G. Bognanno
  • CME / ABIM MOC / CE Released: 7/26/2022
  • Valid for credit through: 7/26/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    IPCE - 0.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, urologists, nurses, nurse practitioners (NPs), pharmacists, and other interprofessional healthcare providers (HCPs) practicing globally who care for individuals with prostate cancer.

The goal of this activity is that learners will be better able to incorporate the latest data into the management of patients with mHSPC.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data for mHSPC regimens that include androgen deprivation therapy (ADT), chemotherapy, and second-generation antiandrogens
    • Strategies to incorporate ADT, chemotherapy, and second-generation antiandrogens for the treatment of patients with mHSPC
  • Have greater competence related to
    • Selecting the appropriate therapy for patients with mHSPC
  • Demonstrate greater confidence in their ability to
    • Incorporate regimens as an interprofessional team with ADT, chemotherapy, and second-generation antiandrogens for patients with mHSPC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Maha Hussain, MD, FACP, FASCO

    Genevieve Teuton Professor of Medicine
    Division of Hem/Onc
    Deputy Director
    Robert H. Lurie Comprehensive Cancer Center
    Northwestern University Feinberg School of Medicine
    Chicago, Illinois, United States

    Disclosures

    Maha Hussain, MD, FACP, FASCO, has the following relevant financial relationships:
    Consultant or advisor for: Astellas; AstraZeneca; Bayer; Bristol Myers Squibb Company; Janssen; Merck; Novartis; Pfizer; Precisca; Tempus
    Research funding from: Arvinas; AstraZeneca; Bayer; Genentech; Pfizer
    Patent beneficiary of: IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753 US 8,185,186 (US patent number) Systems and methods for tissue imaging (issued patent) EP 08745653.9 (EP application number) Systems and methods for tissue imaging (pending) CA 2683805 (Canadian application number) Systems and methods for tissue imaging (pending) US 13/362,500 (US application number) Systems and Methods for Tissue Imaging (continuation application of US 8,185,186) TITLE: METHOD OF TREATING CANCER Docket No: SerialNumber: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011 TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Patent No. 11764656.2-1464 Application Filed on: 26/9/2011

  • Emily Lemke, DNP

    Assistant Professor
    Nurse Practitioner
    Medical College of Wisconsin Cancer Center
    Milwaukee, Wisconsin; United States

    Disclosures

    Emily Lemke, DNP, has no relevant financial relationships

  • Fred Saad, MD, FRCS

    Professor and Chief of Urology
    Director of GU Oncology
    Raymond Garneau Chair in Prostate Cancer
    University of Montreal Hospital Center (CHUM)
    Director, Prostate Cancer Research

    Disclosures

    Fred Saad, MD, FRCS, has no relevant financial relationships.

  • Thomas G. Bognanno

    Patient Expert
    Chair, Board of Directors
    ZERO – The End of Prostate Cancer

    Disclosures

    Thomas G. Bognanno, has the following relevant financial relationships:
    Speaker or member of speakers bureau for: Pfizer

Editors

  • Davecia Ragoonath-Cameron, MS

    Medical Education Director, Medscape, LLC

    Disclosures

    Davecia R. Cameron, MS, has no relevant financial relationships.

  • Yoji Yamaguchi, MA, ELS

    Scientic Content Manager, Medscape, LLC

    Disclosures

    Yoji Yamaguchi, MA, ELS, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Developed through a partnership between Medscape and ZERO – The End of Prostate Cancer.



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Optimizing Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Authors: Maha Hussain, MD, FACP, FASCO; Emily Lemke, DNP; Fred Saad, MD, FRCS; Thomas G. BognannoFaculty and Disclosures

CME / ABIM MOC / CE Released: 7/26/2022

Valid for credit through: 7/26/2023

processing....

Educational Impact Challenge

The goal of this activity is that learners will be better able to incorporate the latest data into the management of patients with mHSPC.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.